Last reviewed · How we verify
Septicemia due to enterococcus — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Unasyn | AMPICILLIN | Bristol-Myers Squibb | Penicillin-class Antibacterial | Transient receptor potential cation channel subfamily M member 4 | 1965-01-01 | |
| Penicillin G Potassium In Plastic Container | Benzylpenicillin | Pfizer | Penicillin-class Antibacterial | 1947-01-01 | ||
| penicillin | penicillin | Karlstad University | Bacterial penicillin-binding protein, Beta-lactamase, Beta-lactamase TEM |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 1 drug in Septicemia due to enterococcus
- Bristol-Myers Squibb · 1 drug in Septicemia due to enterococcus
- Karlstad University · 1 drug in Septicemia due to enterococcus
- Pfizer · 1 drug in Septicemia due to enterococcus
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Septicemia due to enterococcus:
- Septicemia due to enterococcus treatment updates — RSS
- Septicemia due to enterococcus treatment updates — Atom
- Septicemia due to enterococcus treatment updates — JSON
Cite this brief
Drug Landscape (2026). Septicemia due to enterococcus — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/septicemia-due-to-enterococcus. Accessed 2026-06-10.
Related
- Septicemia due to enterococcus full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing